DARZALEX (daratumumab) and DARZALEX FASPRO
Named by the company as a Q2 2026 Innovative Medicine growth driver in multiple myeloma.
What it is
Anti-CD38 antibody for multiple myeloma and other blood cancers. It is one of J&J's largest medicines and the main driver of the oncology franchise. The company gives no dollar sales figure for it in the Q2 2026 release.
Why it matters to the stock. The biggest single medicine in the portfolio, so its growth and any erosion affect the Innovative Medicine outlook most.
News
FDA approves TECVAYLI plus DARZALEX FASPRO for myeloma after one prior line, a potential second-line standard
The FDA approved TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma who have had at least one prior line of therapy.
Product